The evolving natural history of neurophysiologic function in patients with well-controlled diabetes

Journal of the Peripheral Nervous System

Volumn 18, Issue 2, 2013, Pages 153-161

  Gibbons, Christopher H ^a   Freeman, Roy ^a   Tecilazich, Francisco ^a   Dinh, Thanh ^a   Lyons, Thomas E ^a   Gnardellis, Charalambos ^b   Veves, Aristidis ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TECHNOLOGICAL EDUCATIONAL INSTITUTE OF PATRAS   (Greece)

Author keywords

diabetes; natural history; neuropathy; neurophysiology; small fiber

Indexed keywords

ACTION POTENTIAL; ADULT; ARTICLE; DIABETES MELLITUS; DISEASE CONTROL; DISEASE SEVERITY; FEMALE; FOOT; FOREARM; HISTORY; HUMAN; LASER DOPPLER FLOWMETRY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NERVE CONDUCTION; NERVE FIBER; NEUROLOGIC EXAMINATION; NEUROPHYSIOLOGY; PRIORITY JOURNAL; SURAL NERVE;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; ELECTROPHYSIOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION;

EID: 84879361452     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns5.12021     Document Type: Article

References (33)

1. Albers JW, Brown MB, Sima AA, Greene DA, (1996). Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial. Neurology 46: 85-91.
2. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, Waberski BH, Lachin JM, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2010). Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 33: 1090-1096.
3. Bril V, Hirose T, Tomioka S, Buchanan R, Ranirestat Study Group (2009). Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 32: 1256-1260.
4. Caselli A, Rich J, Hanane T, Uccioli L, Veves A, (2003). Role of C-nociceptive fibers in the nerve axon reflex-related vasodilation in diabetes. Neurology 60: 297-300.
5. Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ 3rd, Wolka AM, Vinik AI, (2007). A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 30: 896-902.
6. DCCT Research Group (1988). Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes 37: 476-481.
7. DCCT Research Group (1998). The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 41: 416-423.
8. Donaghue VM, Giurini JM, Rosenblum BI, Weissman PN, Veves A, (1995). Variability in function measurements of three sensory foot nerves in neuropathic diabetic patients. Diabetes Res Clin Pract 29: 37-42.
9. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC, (1997). Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49: 229-239.
10. Gaede P, Lund-Andersen H, Parving HH, Pedersen O, (2008). Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580-591.
11. Gibbons C, Freeman R, (2004). The evaluation of small fiber function-autonomic and quantitative sensory testing. Neurol Clin 22: 683-702 vii.
12. Gibbons CH, Freeman R, Veves A, (2010). Diabetic neuropathy: a cross-sectional study of the relationships among tests of neurophysiology. Diabetes Care 33: 2629-2634.
13. Hamdy O, Abou-Elenin K, LoGerfo FW, Horton ES, Veves A, (2001). Contribution of nerve-axon reflex-related vasodilation to the total skin vasodilation in diabetic patients with and without neuropathy. Diabetes Care 24: 344-349.
14. Hilz MJ, Stemper B, Axelrod FB, Kolodny EH, Neundorfer B, (1999). Quantitative thermal perception testing in adults. J Clin Neurophysiol 16: 462-471.
15. Kilo S, Berghoff M, Hilz M, Freeman R, (2000). Neural and endothelial control of the microcirculation in diabetic peripheral neuropathy. Neurology 54: 1246-1252.
16. Kumar S, Fernando DJ, Veves A, Knowles EA, Young MJ, Boulton AJ, (1991). Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. Diabetes Res Clin Pract 13: 63-67.
17. Malik R, Veves A, Tesfaye S, Smith G, Cameron N, Zochodne D, Lauria G, on behalf of the Toronto Consensus Panel on Diabetic Neuropathy* (2011). Small fiber neuropathy: role in the diagnosis of diabetic sensorimotor polyneuropathy. Diabetes Metab Res Rev. doi: 10.1002/dmrr.1222 [Epub ahead of print].
18. Nilsson PM, (2010). ACCORD and risk-factor control in type 2 diabetes. N Engl J Med 362: 1628-1630.
19. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M, (1995). Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 89-94.
20. van de Poll-Franse LV, Valk GD, Renders CM, Heine RJ, van Eijk JT, (2002). Longitudinal assessment of the development of diabetic polyneuropathy and associated risk factors. Diabet Med 19: 771-776.
21. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM, Albers JW, DCCT/EDIC Research Group (2010). DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 10: 276-282.
22. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS, American Diabetes Association; American College of Cardiology Foundation; American Heart Association (2009). Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119: 351-357.
23. Sosenko JM, Sparling YH, Hu D, Welty T, Howard BV, Lee E, Robbins DC, (1999). Use of the Semmes-Weinstein monofilament in the strong heart study. Risk factors for clinical neuropathy. Diabetes Care 22: 1715-1721.
24. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH, EURODIAB Prospective Complications Study Group (2005). Vascular risk factors and diabetic neuropathy. N Engl J Med 352: 341-350.
25. Toyry JP, Niskanen LK, Lansimies EA, Partanen KP, Uusitupa MI, (1996a). Autonomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 27: 1316-1318.
26. Toyry JP, Niskanen LK, Mantysaari MJ, Lansimies EA, Uusitupa MI, (1996b). Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. Diabetes 45: 308-315.
27. Toyry JP, Partanen JV, Niskanen LK, Lansimies EA, Uusitupa MI, (1997). Divergent development of autonomic and peripheral somatic neuropathies in NIDDM. Diabetologia 40: 953-958.
28. UKPDS Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853.
29. Veves A, Manes C, Murray HJ, Young MJ, Boulton AJ, (1993). Painful neuropathy and foot ulceration in diabetic patients. Diabetes Care 16: 1187-1189.
30. Veves A, Uccioli L, Manes C, Van Acker K, Komninou H, Philippides P, Katsilambros N, De Leeuw I, Menzinger G, Boulton AJ, (1994). Comparison of risk factors for foot problems in diabetic patients attending teaching hospital outpatient clinics in four different European states. Diabet Med 11: 709-713.
31. Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ 3rd, MBBQ Study Group (2005). Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 27: 1164-1180.
32. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL, (2009). Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 58: 1634-1640.
33. Ziegler D, Gries FA, Spuler M, Lessmann F, (1993). The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. Diabet Med 10 (Suppl 2): 82S-86S.